▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #746 by analyst upside · 2026-06-27
BCRX
BioCryst Pharmaceuticals, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+114.3%
implied upside to consensus target
Current Price $9.94
Consensus Target $21.3
Bull Target $32.0
Bear Target $13.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
7
Hold
0
Sell
0
52-Week Low $6.0
52-Week High $10.94
YTD Return +32.5%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 14.6x
EPS (TTM) $-1.78
PEG Ratio 9.39
Dividend Yield N/A
Revenue (TTM) $886M
Profit Margin -51.7%
52-WEEK RANGE
52-Week Low $6.0
52-Week High $10.94
Current Price $9.94
Bear Target $13.0
Bull Target $32.0
● Now $9.94 ● Target $21.3
TRADING DATA
Avg Volume 4.8M
YTD Return +32.5%
Analyst Count 10
Consensus Buy
Upside to Target +114.3%
Last Updated 2026-06-27

ANALYST SUMMARY

BioCryst Pharmaceuticals, Inc. (BCRX) is currently trading at $9.94 with a Wall Street consensus price target of $21.3, implying potential upside of 114.3% over the next 12 months. 10 analysts currently cover BCRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $13.0.

BCRX operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 32.5% year-to-date and is currently trading near the upper end of its 52-week range of $6.0 – $10.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +112.0%
Green Thumb Industries Inc.
$2B · P/E 14.2x · Buy
INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy
PBH +35.2%
Prestige Consumer Healthcare Inc.
$2B · P/E 12.6x · Buy
ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy
OPCH +31.0%
Option Care Health, Inc.
$3B · P/E 16.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BCRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-07 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Needham — Reiterated
Buy → Buy 2026-05-06 20% win rate (5 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-01-30 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-12-15 31% win rate (48 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2025-11-05 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2025-11-04 Building track record
Needham — Reiterated
Buy → Buy 2025-11-04 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →